Slayback Pharma

About:

Slayback Pharma believe every pharmaceutical product exhibits its own unique personality.

Website: http://www.slayback-pharma.com/

Top Investors: Kohlberg Kravis Roberts, Everstone

Description:

Slayback is founded on the principle of “connecting the dots”. This principle translates into their philosophy of connecting one idea with another. The idea is to conceptualize and develop complex generic and specialty drugs. They focus on products that are challenging and highly complex to develop and/or manufacture. It could be a complex oil-in-water emulsion or a sterile long acting injectable using nano-spheres or sterile suspensions with complex particle physics. They have also worked on complex hormonal products with challenging cross-contamination issues. They aim to optimize the use of technology and potential (generated from a strong experience in this field) to develop a value proposition for their customers. Through this process of drug development, they remotely aim at reducing the cost of therapy by bringing expensive branded drugs within the reach of patients.

Total Funding Amount:

$110M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Princeton, New Jersey, United States

Founded Date:

2011-01-01

Contact Email:

contact(AT)slayback-pharma.com

Founders:

Ajay K Singh

Number of Employees:

101-250

Last Funding Date:

2020-01-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai